About Us

Background

  • Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
  • Professor Kataoka and Professor Yokota have codeveloped breakthrough technology enabling drug delivery across the blood-brain barrier (BBB) in close combination with nano-material engineering and neuroscience expertise, respectively.

Corporate profile

(As of October 2017)

Company name Braizon Therapeutics, Inc.
Established October 30, 2015
Business description Research and development of new drugs, diagnostics, and life science research reagents, mainly for use in the CNS area, and the licensing of related intellectual properties, etc.
(Business in the fields of bio and drug discovery based on the outcomes of collaborative research by the University of Tokyo and Tokyo Medical and Dental University.)
Representative
Director & CEO
Mariko Tosu
Paid-in capital $3,444,000 (As of August 10, 2018)
Address Sanyu Bld.201, 3-42-1, Hongo, Bunkyo-ku, Tokyo, 113-0033
Company history October 2015 Established in Bunkyo-ku, Tokyo, based on the outcomes of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
February 2016 Authorized as a bio-venture firm originating from Tokyo Medical and Dental University.

Board members

CEO Mariko Tosu
Board Member Hiromichi Kimura
Board Member Tomohiro Anzai
Board Member Mikio Kawahara
Corporate Auditor Makoto Takeuchi
Mariko Tosu:CEO

After researching at National Cancer Research institute and Medical Science Institute of Tokyo University, Dr. Tosu joined Amersham Pharmacia Biotech KK(present: GE Healthcare Japan) in 1991 as a senior research scientist for research project supported by NEDO (New Energy and Industrial Technology Development Organization) and subsequently held the position of the technical service and marketing. After then she moved to Nihon Millipore (present: Merk-Millipore Japan), Invitrogen KK (present: Thermo-Fisher Japan) and Beckman Coulter KK as the marketing head or the division head. And then she became the president of Fluidigm KK in 2013 and retired in Feb 2017. Dr. Tosu assumed the post of CEO at Braizon Therapeutics in March 2017.
Graduated from Tokyo university of Pharmacy. Pharmacist
Ph.D in Pharmacy from Meiji Pharmaceutical University

Hiromichi Kimura:Board Member

After working at the pharmaceutical division of Kyowa Hakko Kogyo and J.P. Morgan as Vice President, Mergers & Acquisitions Division, Dr. Kimura became President and Representative Director of Amersham Pharmacia Biotech KK (present: GE Healthcare Japan), Monsanto Japan Ltd. (present: Pfizer Japan Inc.), and subsequently CEO of HuBit Genomix Inc.
In March 2004, Dr. Kimura co-founded Fast Track Initiative (FTI) Inc. and became President of the partnership.
Graduated from the faculty of pharmaceutical sciences, the University of Tokyo.
Ph.D. in pharmaceutical sciences from the University of Tokyo
Doctor of Pharmacy
MBA from the Graduate School of Business, Stanford University

Tomohiro Anzai:Board Member

Dr. Anzai joined Arthur D. Little (Japan) Inc. where he was engaged in management consulting for biotechnology businesses both inside and outside Japan. He dealt with business challenge for a wide range of companies in the fields of life sciences and health care, including pharmaceutical manufacturers, diagnostic pharmaceuticals manufacturers, equipment for research and development/reagent manufactures, and food manufacturers. He was also involved in R&D and business strategy development, focusing on company-wide strategic planning and implementation support. In January 2006, Dr. Anzai joined FTI Inc. and has been in charge of various areas, from selecting investment projects, to founding and developing companies, and investment recovery.
Graduated from the Department of Biological Sciences, Faculty of Science, the University of Tokyo
Ph.D. in molecular biology from the Graduate School of Frontier Sciences, the University of Tokyo
Special researcher of the Japan Society for the Promotion of Science
Doctor of Life Science

Mikio Kawahara:Board Member

Since 2016, Mr. Mikio Kawahara has been Head of Investment and Business Development at UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), the University of Tokyo's investment arm for innovations and start-ups.
Before joining UTokyo IPC, Mr. Kawahara worked for Toppan Printing Co., Ltd. in 1997. At Toppan, he launched his career as a computer engineer at the firm's research center. After moving to the Corporate Planning Division at the firm's headquarters, he engaged in many diversified projects involving corporate restructuring, strategic alliances, and M&As. In 2007, he established Riken Genesis Co., Ltd., a new biotech start-up from RIKEN Research Institute, and led its management as Chief Operating Officer. In this role, he pioneered the personalized medicine business in Japan.
From 2014, he concurrently served as President and CEO of BNA Inc., a biotech venture incubated at Osaka University.
He assumed the post of Board member at Braizon Therapeutics, Inc. in August 2018.
Master of Mathematical Engineering, Graduate School of Engineering, the University of Tokyo.
MBA, Kellogg School of Management, Northwestern University.
Master of Engineering Management, McCormick School of Engineering, Northwestern University.

Makoto Takeuchi:Corporate Auditor

Mr. Takeuchi previously spent long term at Yamanouchi Pharmaceutical Co., Ltd. and Astellas Pharma Inc. in roles of increasing responsibility in the Research Division and ultimately up to Senior Corporate Executive and Head of External Relations. He has extensive experience in industrial pharmaceutical research, especially in g inflammation and bone metabolism areas, and he was deeply involved in the discovery and launch of new medicines such as Minodronate and Solifenacin for the treatment of osteoporosis and overactive bladder, respectively. He also studied abroad at the University of Pennsylvania (Prof. Amos Smith III) for one year from 2001.
He has also worked for the Japan Pharmaceutical Manufacturers Association (JPMA) as chairman of the Pharmaceutical Industrial Policy Committee and R & D Committee, and for the Forum for Innovative Regenerative Medicine (FIRM) as a vice chairman and so on.
He graduated from the Graduate School of Medicine and Pharmaceutical Science, Toyama Medical and Pharmaceutical University. A lecturer of Forefront of Drug Discovery Seminar hosted by Foundation Pharmaceutical Council. A member of the verification committee for the National Institute of Advanced Industrial Science and Technology self-evaluation.